Hydroxychloroquine treatment downregulates systemic interferon activation in primary Sjögren’s syndrome in the JOQUER randomized trial

OBJECTIVE: HCQ is frequently used to treat primary SS (pSS), but evidence for its efficacy is limited. HCQ blocks IFN activation, which is present in half of the pSS patients. The effect of HCQ treatment on the expression of IFN-stimulated genes (ISGs) was studied in pSS. Furthermore, HCQ-treated pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Bodewes, Iris L A, Gottenberg, Jacques-Eric, van Helden-Meeuwsen, Cornelia G, Mariette, Xavier, Versnel, Marjan A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Clinical Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6909893/
https://www.ncbi.nlm.nih.gov/pubmed/31237947
http://dx.doi.org/10.1093/rheumatology/kez242

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6909893/
https://www.ncbi.nlm.nih.gov/pubmed/31237947
http://dx.doi.org/10.1093/rheumatology/kez242

Ejemplares similares